- CH₣311.46bn
- CH₣337.55bn
- CH₣61.52bn
Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
Factbox: Major drugmakers turn to China for licensing deals
Brief: Roche Says Giredrestrant Combination Improved Progression-Free Survival In Phase III Study
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Major drugmakers turn to China for licensing deals
Brief: Roche Says FDA Accepts Roche NDA For Fenebrutinib Under Priority Review
Roche outlines plans to move towards autonomous AI labs
Regarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Brief: FDA Approves Gazyva To Treat Idiopathic Nephrotic Syndrome In Patients 2 Years And Older
Roche, Atavistik Bio sign drug-discovery deal worth up to $2 billion (updated)
Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion
Brief: Atavistik Bio, Roche Enter Drug Discovery Collaboration
Brief: Basecamp Research Raises $140 Mln In Oversubscribed Series C Funding
Brief: Roche Posts Interim Data Regarding Sefaxersen
Roche proposes former Takeda CEO for board seat
Brief: Roche Board Proposes Christophe Weber For Election To Board
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
European drugmakers call for faster trials, more spending to compete with US, China
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up